Naftidrofuryl
![]() |
|
Clinical data | |
---|---|
Trade names | Praxilene |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Biological half-life | 1 - 3.5 hours |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.045.960 |
Chemical and physical data | |
Formula | C24H33NO3 |
Molar mass | 383.524 g/mol |
3D model (Jmol) | |
|
|
|
|
(verify) |
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.
Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.
Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[4]
Naftidrofuryl may be effective for relieving the pain of muscle cramps.[5]
Adverse Effects[edit]
Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[6]
Synthesis[edit]
![](http://web.archive.org./web/20170406084636im_/https://upload.wikimedia.org/wikipedia/commons/thumb/8/87/Nafronyl_synthesis.svg/700px-Nafronyl_synthesis.svg.png)
See also[edit]
References[edit]
- ^ Peter Lanzer; Eric J. Topol (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9.
- ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.
- ^ Aly, Saida Abdel Regal; Hossain, Murad; Bhuiyan, Mohiuddin Ahmed; Nakamura, Takashi; Nagatomo, Takafumi (2009). "Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–450. doi:10.1254/jphs.09124FP. ISSN 1347-8613.
- ^ http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm
- ^ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
- ^ Brayfield, A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.
- ^ Szarvasi et al., Compt. Rend. 260, 3095 (1965).
- ^ Bull. Soc. Chim. Fr. 1966, 1838.
![]() |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |